T1	Outcomes 471 497	antitumor activity of TMZ.
T2	Outcomes 1062 1077	Tumor responses
T3	Outcomes 1187 1219	median time to progression (TTP)
T4	Outcomes 1273 1301	median overall survival (OS)
T5	Outcomes 1399 1435	objective response rates, TTP and OS
T6	Outcomes 1521 1619	anemia, leukopenia, neutropenia, thrombocytopenia, fatigue, constipation and arthralgias/myalgias.
T7	Outcomes 1649 1669	grade 3 and 4 emesis
T8	Outcomes 1706 1722	No clear benefit
T9	Outcomes 1735 1761	response rates, median TTP
T10	Outcomes 1884 1905	grade 3 and 4 emesis.
